☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Macular Degeneration
Genentech's Susvimo Receives the US FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration
October 25, 2021
Roche Report the US FDA's Acceptance of BLA for Port Delivery System with Ranibizumab to Treat Neovascular Age-Related Macular Deg...
June 24, 2021
Samsung Bioepis Reports Results of SB11 (proposed biosimilar ranibizumab) in P-III Study for Neovascular Age-Related Macular Degen...
May 19, 2020
Novartis' Beovu (brolucizumab) Receives EC's Approval for Wet Age-Related Macular Degeneration
February 17, 2020
Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)
September 4, 2024
Insights+ Key Biosimilars Events of August 2024
September 3, 2024
Sandoz Reports the US FDA’s Approval of Enzeevu (Biosimilar, Eylea) to Treat Neovascular Age-Related Macular Degeneration
August 12, 2024
Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration
August 5, 2024
Roche’s Vabysmo Prefilled Syringe Receives the US FDA’s Approval for Vision Loss
July 5, 2024
Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)
July 1, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.